Cargando…
Chronic mucocutaneous candidiasis: characterization of a family with STAT‐1 gain‐of‐function and development of an ex‐vivo assay for Th17 deficiency of diagnostic utility
Chronic mucocutaneous candidiasis (CMC) is characterized by recurrent and persistent superficial infections, with Candida albicans affecting the mucous membranes, skin and nails. It can be acquired or caused by primary immune deficiencies, particularly those that impair interleukin (IL)−17 and IL‐22...
Autores principales: | Dhalla, F., Fox, H., Davenport, E. E., Sadler, R., Anzilotti, C., van Schouwenburg, P. A., Ferry, B., Chapel, H., Knight, J. C., Patel, S. Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837241/ https://www.ncbi.nlm.nih.gov/pubmed/26621323 http://dx.doi.org/10.1111/cei.12746 |
Ejemplares similares
-
Immunoprofiling of monocytes in STAT1 gain-of-function chronic mucocutaneous candidiasis
por: Bloomfield, Marketa, et al.
Publicado: (2022) -
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis
por: Liu, Luyan, et al.
Publicado: (2011) -
Three Adult Cases of STAT1 Gain-of-Function with Chronic Mucocutaneous Candidiasis Treated with JAK Inhibitors
por: Borgström, Emilie W., et al.
Publicado: (2022) -
The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1
por: Depner, Mark, et al.
Publicado: (2015) -
Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy
por: Huppler, Anna R, et al.
Publicado: (2012)